Mycobacterium bovis BCG-based vaccines against tuberculosis: novel developments.
Mycobacterium bovis Bacille Calmette-Guérin (BCG) is one of the most widely used vaccines. Modern techniques in genome manipulation allow the construction of recombinant (r)-BCG strains that can be employed as highly immunogenic vaccines against tuberculosis (TB) with an enhanced safety profile. In addition, the development of novel procedures to cultivate BCG will allow the large-scale production of future BCG-based vaccines.
Dietrich
Guido
G
Berna Biotech Ltd, Bacterial Vaccine Research, Rehhagstr 79, CH-3018, Berne, Switzerland. guido.dietrich@bernabiotech.com
Viret
Jean-Francois
JF
Hess
Jürgen
J
D000818:Animals; D001500:BCG Vaccine / Q000009:adverse effects / Q000235:genetics / Q000276:immunology*; D006801:Humans; D009163:Mycobacterium bovis / Q000235:genetics / Q000254:growth & development / Q000276:immunology*; D013678:Technology, Pharmaceutical; D014397:Tuberculosis, Pulmonary / Q000453:epidemiology / Q000276:immunology / Q000517:prevention & control*; D014614:Vaccines, Synthetic / Q000009:adverse effects / Q000235:genetics / Q000276:immunology
D001500:BCG Vaccine; D014614:Vaccines, Synthetic